Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 1
1980 1
1984 1
1986 1
1987 1
1990 1
1992 1
1993 1
1994 5
1995 5
1996 2
1997 2
1998 3
1999 3
2000 7
2001 1
2002 1
2004 1
2005 6
2006 4
2008 1
2010 1
2011 3
2012 1
2013 2
2014 2
2015 4
2016 8
2017 8
2018 10
2019 7
2020 4
2021 3
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Results by year

Filters applied: . Clear all
Page 1
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O'Rourke M, Stephenson JJ, Curti BD, Urba WJ, Brell JM, Funchain P, Kendra KL, Ikeguchi AP, Jaslowski A, Bane CL, Taylor MA, Bajaj M, Conry RM, Ellis RJ, Logan TF, Laudi N, Sosman JA, Crockett DG, Pecora AL, Okazaki IJ, Reganti S, Chandra S, Guild S, Chen HX, Streicher HZ, Wolchok JD, Ribas A, Kirkwood JM. Atkins MB, et al. Among authors: conry rm. J Clin Oncol. 2023 Jan 10;41(2):186-197. doi: 10.1200/JCO.22.01763. Epub 2022 Sep 27. J Clin Oncol. 2023. PMID: 36166727 Free PMC article. Clinical Trial.
Sorafenib for Advanced and Refractory Desmoid Tumors.
Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, Pishvaian MJ, Riedel RF, Sabagh T, Tap WD, Horvat N, Basch E, Schwartz LH, Maki RG, Agaram NP, Lefkowitz RA, Mazaheri Y, Yamashita R, Wright JJ, Dueck AC, Schwartz GK. Gounder MM, et al. Among authors: conry rm. N Engl J Med. 2018 Dec 20;379(25):2417-2428. doi: 10.1056/NEJMoa1805052. N Engl J Med. 2018. PMID: 30575484 Free PMC article. Clinical Trial.
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.
Grossmann KF, Othus M, Patel SP, Tarhini AA, Sondak VK, Knopp MV, Petrella TM, Truong TG, Khushalani NI, Cohen JV, Buchbinder EI, Kendra K, Funchain P, Lewis KD, Conry RM, Chmielowski B, Kudchadkar RR, Johnson DB, Li H, Moon J, Eroglu Z, Gastman B, Kovacsovics-Bankowski M, Gunturu KS, Ebbinghaus SW, Ahsan S, Ibrahim N, Sharon E, Korde LA, Kirkwood JM, Ribas A. Grossmann KF, et al. Among authors: conry rm. Cancer Discov. 2022 Mar 1;12(3):644-653. doi: 10.1158/2159-8290.CD-21-1141. Cancer Discov. 2022. PMID: 34764195 Free PMC article. Clinical Trial.
Talimogene laherparepvec: First in class oncolytic virotherapy.
Conry RM, Westbrook B, McKee S, Norwood TG. Conry RM, et al. Hum Vaccin Immunother. 2018 Apr 3;14(4):839-846. doi: 10.1080/21645515.2017.1412896. Epub 2018 Feb 22. Hum Vaccin Immunother. 2018. PMID: 29420123 Free PMC article. Review.
Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial.
Dummer R, Gyorki DE, Hyngstrom J, Berger AC, Conry R, Demidov L, Sharma A, Treichel SA, Radcliffe H, Gorski KS, Anderson A, Chan E, Faries M, Ross MI. Dummer R, et al. Among authors: conry r. Nat Med. 2021 Oct;27(10):1789-1796. doi: 10.1038/s41591-021-01510-7. Epub 2021 Oct 4. Nat Med. 2021. PMID: 34608333 Clinical Trial.
Paediatric hospital antimicrobial guidelines: a national UK review.
Shears A, Hoskyns L, Flinders P, Conry R, McMaster P; UK-PAS Committee. Shears A, et al. Among authors: conry r. Arch Dis Child. 2023 Nov;108(11):946-947. doi: 10.1136/archdischild-2023-325854. Epub 2023 Aug 27. Arch Dis Child. 2023. PMID: 37640430 No abstract available.
Human immune response to monoclonal antibodies.
Khazaeli MB, Conry RM, LoBuglio AF. Khazaeli MB, et al. Among authors: conry rm. J Immunother Emphasis Tumor Immunol. 1994 Jan;15(1):42-52. doi: 10.1097/00002371-199401000-00006. J Immunother Emphasis Tumor Immunol. 1994. PMID: 8110730 Review.
Smoldering myocarditis following immune checkpoint blockade.
Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, Gertler AS, Moslehi JJ, Conry RM. Norwood TG, et al. Among authors: conry rm. J Immunother Cancer. 2017 Nov 21;5(1):91. doi: 10.1186/s40425-017-0296-4. J Immunother Cancer. 2017. PMID: 29157297 Free PMC article.
Correlates of response and outcomes with talimogene laherperpvec.
Zhou AY, Wang DY, McKee S, Ye F, Wen CC, Wallace DE, Ancell KK, Conry RM, Johnson DB. Zhou AY, et al. Among authors: conry rm. J Surg Oncol. 2019 Sep;120(3):558-564. doi: 10.1002/jso.25601. Epub 2019 Jul 2. J Surg Oncol. 2019. PMID: 31264725 Free PMC article.
100 results